Pulmonary fibrosis corresponds to the end stage of various pulmonary diseases that are characterized by the growth offibroblasts and the increase of collagen deposition within the alveolar walls (reviewed in references 1-3). Their pathogenesis is poorly understood and the involvement of fibroblast growth factors, known to be produced by alveolar macrophages, is suspected (4, 5) . TNFalcachectin is one of the cytokines produced by macrophages activated by inflammatory agents such as bacterial LPS. TNF has a wide range of activities (reviewed in references 6 and 7), one ofthese being a growth-promoting activity upon fibroblast cell lines (8) . In vivo, we recently found that a continuous infusion of TNF within the hypodermis stimulated the growth offibroblasts and led to an increase of the local collagen deposition (Piguet, P R, G. E. Grau, and P. Vassalli, manuscript submitted for publication) .
Bleomycin corresponds to a group of glycopeptides that are used for the chemotherapy of cancer, a therapy that is, however, limited by the occurrence of pulmonary fibrosis . In rodents the administration of bleomycin has been extensively used as a model of pulmonary fibrosis (reviewed in reference 2). In the present study, the role ofTNF in the bleomycin-induced pneumopathy and fibrosis was investigated . The evolution of the fibrotic process was found to be associated with an increase in the level of lung TNF mRNA, suggesting an increase in local TNF production . Furthermore, injection of rabbit antiTNF antibody markedly prevented the development of pulmonary lesions and fibrosis. These experiments are consistent with a key role for TNF in at least some types of pulmonary fibrosis.
or GK 1 .5, a rat IgG2b anti-CD4, as described previously (9) . The controls were injected with HBSS only.
Assayfor TNF. TNF activity was determined using the lysis of the L929 cell line (10) . Lightand Electron Microscopy. The lungs were fixed by intracheal instillation offormol sublimate and embedded within paraffin . Sections were stained by the hematoxilin-eosin and Masson trichrome stains. For a semiquantitative evaluation of the extent of lung damage, sections from the right and left lung of individual mice were projected on a multipurpose grid with 168 points. The number of points falling on normal or severely damaged tissue was established . This gave an approximative evaluation of the percentage ofdamaged parenchyma. For embedding in epon, the lungs were fixed by intratracheal instillation of 2% glutaraldehyde in cacodylate buffer (0.1 M, pH 7.2). Sections were prepared from three blocks from the left lung for each individual mouse and were stained with toluidine blue. For EM, 700-A ultrathin sections were stained with 1% uranyl acetate in 100% methanol and lead citrate and were examined with an electron microscope (400; Philips Electronic Instruments, Inc., Mahwah, NJ) at 80 Kv.
Northern Blot Analysis of TNF-a, IL-1-a, and Granulocyte-macrophage CSF (GM-CSF)' mRNAs in Total Lung RNA. The lungs were washed with saline and frozen in liquid nitrogen . They were subsequently thawed by mincing in a guanidine-thiocyanate solution and the total lung RNA was isolated by guanidine-thiocyanate/cesium chloride centrifugation (11) . Northern blots were performed as described elsewhere (12) . Briefly, RNAs denatured with glyoxal were separated on 1.2% agarose gels (4 jig/lane) and were transferred onto nylon membranes. Equality of sample loading and efficiency of the transfer were controlled by staining with methylene blue. Filters were hybridized with 12 P-labeled cRNA probes (13) . The probes for TNFa, IL-1-a, and GM-CSF have been described elsewhere (12, 13) .
Rabbit Anti-mouse TNFAntibodies. Mouse rTNFa was a kind gift from B. Allet Glaxo, IMB, Geneva, Switzerland . Purification of the cytokine and the preparation of rabbit anti-TNF antibody have been described previously (14) . IgG fraction from antiTNF or normal serum were deaggregated by ultracentrifugation at 150,000 g for 150 min, and 1 mg was injected intravenously.
Evaluation of the Lung Hydroxyproline Content. The total lung hydroxyproline concentration was determined using described methods (15) . Briefly, the lungs were submitted to an acid hydrolysis, the hydrolysate was neutralized, extracted with phenol-chloroform-isoamylalcool, and the hydroxyproline concentraton was determined colorimetrically (15) .
Statistical Evaluation . Statistical analysis was performed using the nonparametric MannWhitney U test.
Results

Intratracheal Instillation ofBleomycin Increases the TNF mRNA Level in the Lung Whereas
Those of Interleukin 1 and GM-CSF Remain Undetectable. Bleomycin administration did not lead to a detectable increase of the serum TNF activity (not shown). However, evidence for a local increase of TNF production was provided by the analysis of the lung TNF mRNA level. RNA from the lungs of individual mice were extracted and analyzed by Northern blot hybridization at various times after intracheal instillation of bleomycin ( Fig. 1 ). An increase ofTNF mRNA level was not apparent 2 d after bleomycin instillation (not shown), but was detectable in 12 mice killed between day 5 and 15 ( Fig. 1) . In contrast, the mRNAs for IL-1 and GM-CSF were not detectable after instillation of bleomycin, but evident 1-2 h after LPS injection (Fig. 2) .
Influence of AntiTNF-ce Antibody upon the Systemic and Pulmonary Effects of Bleomycin Administration. 1 mg of control or antiTNF IgG was injected on days 1 and 8 after I Abbreviation used in this paper: GM-CSF, granulocyte-macrophage CSF 657 the intratracheal administration of 0.1 U of bleomycin, and the mice were killed on day 15. AntiTNF activity was detectable in the serum during the treatment (14) . The bleomycin instillation induced some mortality, ranging between 0 and 30% in different experiments, and this was not significantly affected by the treatment with antiTNF IgG (not shown) . Study of histological sections suggested that mortality was related either to extensive lung damage (see below) or to infectious complications that were occasionally observed in mice receiving antiTNF IgG. Indeed, this treatment is known to compromise the resistance to some bacteria (16) . Bleomycin administration also led to a weight loss that was partially prevented by antiTNF antibody. The body weight of the saline instilled controls were of77% (±12) or 85% ( t 17) for the mice treated with nonimmune or antiTNF IgG, respectively (mean t SD on day 15 after bleomycin intratracheal instillation, difference not significant at p > 0.05) .
Study of the lung by light microscopy 15 d after intratracheal instillation ofbleomycin showed areas of increase of the cellularity of the alveolar septa associated with a total disruption of the alveolar architecture (Fig . 3) . Collagen deposition, revealed with the trichrome stain, was seen in the most severely damaged area . Because of their heterogeneity in the different lobes, these alterations were difficult to quantify. Sections from the right and left lungs of seven mice treated with antiTNF or nonimmune IgG were examined . The severely damaged area (i .e ., disruption of the alveolae and presence of collagen) represented 45 ( ± 25) and 15 % ( t 12) for the mice treated with nonimmune and antiTNF IgG, respectively (mean t SD).
To evaluate more directly the collagen deposition, the total lung hydroxyproline content was determined . After single intratracheal administration of bleomycin, the lung hydroxyproline content was increased by -50% after 15 d. This increase was nearly completely prevented by injection of antiTNF antibody (Fig . 4) .
Role of T Lymphocytes in the Pneumopathy and the TNF mRNA Accumulation. Since athymic nude mice are resistant to the bleomycin-induced pneumopathy (17), T lymphocytes are suspected of being involved . It has been shown previously that treatment in vivo with anti CD4 or CD8 mAb results in significant or complete depletion of the respective T lymphocyte subset (9) . The pulmonary fibrosis, measured by the lung hydroxyproline content, was to some extent attenuated by the deletion of the CD4 or the CD8 T lymphocyte subset and completely prevented by treatment Total lung hydroxyproline of mice instilled with bleomycin and treated with anti-T lymphocyte subset mAb. Mean( t SD) ofthe values observed with more than six mice per group. with both mAbs (Fig. 5) . Furthermore, the bleomycin-induced increase of TNF mRNA level was prevented by the combined treatment with the anti-CD4 and CD8 mAbs, when examined on day 5 ( Fig. 1) or 15 (not shown) .
Effect ofAnti-TNFAntibody on Pulmonary Lesions Produced by Intraperitoneal Administration ofBleomycin. Administration of bleomycin by intraperitoneal injection does not lead to a rapid fibrosis (18) ; 15 d after a continuous injection of a total dose of 2 U of bleomycin, the increase of the lung collagen content, measured by the total hydroxyproline content, was N5% above the controls receiving the solvent only (not shown) . However, an alveolar damage was evident that, in contrast to that induced by intratracheal instillation, was diffuse and therefore easier to quantify. Alveolar oedema and thickening of the alveolar septa were evident by light microscopy (Fig. 6 B) , while epithelial and endothelial cells damage were evident when examined on the electron micrographs (Fig. 6 D) . These alterations were attenuated or absent in mice passively immunized with anti TNF IgG (Fig . 6, A-D) .
Discussion
The administration of bleomycin in rodents is a model for alveolar damage and pulmonary fibrosis (2) . The reason for the predominant pulmonary damage after bleomycin injection is probably related to the fate of the drug, which is found localized within the alveolar epithelium 3-4 d after an intravenous injection (19) . 5 d after intratracheal injection, an increase of the TNF mRNA level is evident (Fig .  1 ) . This increase is relatively moderate in comparison with that induced by a lethal dose of LPS (Fig . 1) , but much more sustained since it is detectable during 2 wk after a single bleomycin injection, compared with only 2-3 h after LPS. This observation raises the question of whether a local increase of the TNF production plays some role in the antineoplastic effects of bleomycin.
The bleomycin-induced pneumopathy is not a direct result of a toxicity of the drug since it involves a T cell-mediated immune response. This is indicated by an influx of T lymphocytes within the lung 3-4 d after bleomycin instillation (20) and by the resistance of the athymic nude mice to bleomycin (17) . In agreement with those observations, the present experiments provide two additional informations . First, either the CD4+ or CD8 * T lymphocyte subset alone is capable of inducing some degree of fibrotic response (Fig . . 5) , and second, the presence of the T lymphocytes is required for an increase of pulmonary TNF mRNA level (Fig . 1) .
The cellular origin of the pulmonary TNF has not yet been established and may involve more than one cell variety. Macrophages are in quantitative terms the most important producers ofTNF (6, 7) , and the involvement ofthe alveolar and interstitial population is likely. T lymphocytes can also release TNF (21) , but the absence of detectable GM-CSF mRNA (Fig . 2) , a cytokine usually produced by activated T lymphocytes, suggests that their number within the lung and their direct contribution to the TNF production is moderate . It appears more likely that T lymphocytes increase, by the secretion ofother cytokines, both the number of macrophages and their activation to secrete TNF, as appears to be the case in other types of T cell-induced and TNF-mediated immunopathological reactions (22) .
The various components of bleomycin-induced pneumopathy (i.e., alveolar damage, growth ofinterstitial fibroblasts, deposition of collagen [18, 19, 23] ) were influenced by the administration of antiTNF antibody. This observation has to be related to the effects of TNF upon the alveolar walls and the fibrotic process. When delivered intravenously, TNF induces a diffuse alveolar damage, notably with necrosis of alveolar epithelial and endothelial cells (24, 25) . TNF also exerts a growth-promoting activity upon fibroblasts, since a subcutaneous continuous infusion leads to a marked increase of fibroblast proliferation and collagen deposition (Piguet, P F, G. E. Grau, and P Vassalli, manuscript submitted for publication) . Thus, the susceptibility of the lesions to the antiTNF antibody, as well as the capacity of TNF to induce alveolar damage and fibrosis, strongly suggests that TNF is indeed the effector of both alveolar damage and fibrosis. A variety ofother cytokines have been shown to influence fibroblasts in vitro, such as platelet-derived growth factor (26), IL-1 (27) , and TGF0 (28) . A further element of complexity results from the possibility that these mediators may induce each other, as it has been demonstrated for the induction ofplateletderived growth factor and IL-1 by TNF (29) . In this context, the striking influence of anti TNF antibody upon the collagen deposition might indicate that other mediators are not produced in significant quantities, an interpretation that, in the case of IL-1, is supported by the absence of detectable IL-1 mRNA (Fig. 2) . Alternatively, or in addition, their involvement might be dependent upon THE
In conclusion, the following evidences are in favor of a key role of TNF in the various components of the bleomycin-induced pneumopathy: first, TNF can induce alveolar damage, fibroblast growth, and collagen deposition; second, a single injection of bleomycin induces a sustained increase of the TNF mRNA level within the lung; and third, antiTNF antibody prevents the bleomycin-induced alveolar damage, growth of fibroblasts, and collagen deposition. Recent experiments in our laboratory indicate that this conclusion is also valid for pulmonary fibrosis induced by silica particles.
Summary
The role of TNFa/cachectin in the pneumopathy elicited by bleomycin has been investigated . After a single intratracheal bleomycin instillation, an increase of the lung TNFa mRNA level was evident, from days 5 to 15, as shown by Northern gel analysis ofwhole lung RNA. In contrast, lung IL-1-a and GM-CSF mRNA were not detectable. In mice passively immunized with rabbit anti-mouse TNFa IgG, the bleomycin-induced collagen deposition, evaluated by the total lung hydroxyproline assay on day 15, was prevented. Depletion of the CD4 and CD8 T lymphocytes by an in vivo treatment with mAb prevented the bleomycin-induced increase ofTNF mRNA level and fibrosis. After an administration of bleomycin in continuous intraperitoneal perfusion, the diffuse alveolar damage observed by light and electron microscopy was almost completely prevented by anti TNF antibody. These results indicate that in response to bleomycin, the T lymphocytes induce, by an undefined mechanism, an increase of the pulmonary TNF production, which leads to alveolar damage, growth of fibroblast, and collagen deposition.
